Drug Innovation
Commentary
Catching Breast Cancer Early Is Still Hard. Melania Trump Can Help
The cost of finding breast cancer late can be staggering–both in dollars and in years of life. A new study by researchers at the National Cancer Institute and American Cancer Society found that, among Medicare beneficiaries, first-year oral prescription drug costs averaged roughly $700 for localized breast cancer—and about $25,000 ...
Drug Innovation
PRI Warns Proposed COINS Act Rule Could Undermine America’s Medical Innovation Leadership
Yesterday, the Treasury Department issued a proposed rule implementing the Comprehensive Outbound Investment National Security (COINS) Act, which restricts certain U.S. investments in China and other countries of concern. The proposal would expand existing outbound investment restrictions to include biotechnology. Sally C. Pipes, President and CEO of the Pacific Research ...
Commentary
Peptide Dangers Result in Hospitalizations
The peptide market has raced far ahead of both the science and the safeguards meant to protect patients. Federal regulators need to take the explosion of unapproved injectable peptides far more seriously — and target the sellers and suppliers fueling it. Peptide use has grown well beyond a handful of ...
Commentary
The GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Too
The U.S. Food and Drug Administration’s effort to rein in mass-market copies of blockbuster GLP-1 drugs just survived a major legal challenge. Last month, the U.S. Court of Appeals for the Fifth Circuit upheld the agency’s determination that the shortage of semaglutide—the active ingredient in Ozempic and Wegovy—is over. In ...
Commentary
The first mRNA flu vaccine may be just the beginning
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it. Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard ...
Commentary
CMS Undermining Next Generation of Medicines
Some of the biggest advances in medicine don’t come from discovering entirely new drugs. They come from making existing ones easier to take, faster to administer, safer, and more effective. A new proposal from the Centers for Medicare and Medicaid Services could make those improvements far less common. The agency ...
Drug Innovation
California Supreme Court Decision Protects Future Medical Innovation
The Pacific Research Institute – the non-partisan, California-based, free-market think tank – today hailed a landmark California Supreme Court decision protecting future medical innovation. The ruling in the Gilead Tenofir Cases overturns a lower court decision that threatened to expose pharmaceutical innovators to sweeping new liability for decisions about the ...
Biosimilars
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Drug Innovation
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Commentary
Americans Get Medicines First – Why?
Americans hear a lot these days about how Europe has healthcare all figured out. Progressives love pointing to countries like Britain, France, and Canada as models America should follow — especially when it comes to prescription drug prices. What they rarely mention is the price those countries pay for government-controlled ...
Catching Breast Cancer Early Is Still Hard. Melania Trump Can Help
The cost of finding breast cancer late can be staggering–both in dollars and in years of life. A new study by researchers at the National Cancer Institute and American Cancer Society found that, among Medicare beneficiaries, first-year oral prescription drug costs averaged roughly $700 for localized breast cancer—and about $25,000 ...
PRI Warns Proposed COINS Act Rule Could Undermine America’s Medical Innovation Leadership
Yesterday, the Treasury Department issued a proposed rule implementing the Comprehensive Outbound Investment National Security (COINS) Act, which restricts certain U.S. investments in China and other countries of concern. The proposal would expand existing outbound investment restrictions to include biotechnology. Sally C. Pipes, President and CEO of the Pacific Research ...
Peptide Dangers Result in Hospitalizations
The peptide market has raced far ahead of both the science and the safeguards meant to protect patients. Federal regulators need to take the explosion of unapproved injectable peptides far more seriously — and target the sellers and suppliers fueling it. Peptide use has grown well beyond a handful of ...
The GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Too
The U.S. Food and Drug Administration’s effort to rein in mass-market copies of blockbuster GLP-1 drugs just survived a major legal challenge. Last month, the U.S. Court of Appeals for the Fifth Circuit upheld the agency’s determination that the shortage of semaglutide—the active ingredient in Ozempic and Wegovy—is over. In ...
The first mRNA flu vaccine may be just the beginning
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it. Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard ...
CMS Undermining Next Generation of Medicines
Some of the biggest advances in medicine don’t come from discovering entirely new drugs. They come from making existing ones easier to take, faster to administer, safer, and more effective. A new proposal from the Centers for Medicare and Medicaid Services could make those improvements far less common. The agency ...
California Supreme Court Decision Protects Future Medical Innovation
The Pacific Research Institute – the non-partisan, California-based, free-market think tank – today hailed a landmark California Supreme Court decision protecting future medical innovation. The ruling in the Gilead Tenofir Cases overturns a lower court decision that threatened to expose pharmaceutical innovators to sweeping new liability for decisions about the ...
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Americans Get Medicines First – Why?
Americans hear a lot these days about how Europe has healthcare all figured out. Progressives love pointing to countries like Britain, France, and Canada as models America should follow — especially when it comes to prescription drug prices. What they rarely mention is the price those countries pay for government-controlled ...